Literature DB >> 2022477

Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer.

G Cortesina1, A De Stefani, E Galeazzi, G P Cavallo, C Jemma, M Giovarelli, S Vai, G Forni.   

Abstract

Twenty patients with recurrent, inoperable head and neck squamous cell carcinoma received perilymphatic injections of natural interleukin-2 (nIL-2) for 10 days. Ten patients received 200 units (U) of nIL-2; five 1,000 U; and five 5,000 U. Irrespective of the location of the recurrence, the injections were always performed 1.5 cm below the insertion of the sternocleidomastoid muscle on the mastoid. When the ipsilateral lymphatic chain was still present, they were performed on the same side as the tumor site, whereas when it had been stripped as a result of previous surgery, they were contralateral. Patients who had undergone bilateral neck dissection were injected on the tumor side. Whenever possible, the treatment was repeated after 45-day intervals. In 13 patients (65%) with bilateral or contralateral lymph nodes, complete or partial disappearance of the lesion was observed. Despite these marked responses, the tumor always relapsed, and subsequent IL-2 courses were poorly effective. There were no systemic disturbances during or after treatment, but only moderate local swelling and pain.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2022477     DOI: 10.1002/hed.2880130208

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  9 in total

Review 1.  [Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].

Authors:  T K Hoffmann; T L Whiteside; H Bier
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

2.  (123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma.

Authors:  David Loose; Alberto Signore; Ludovicus Staelens; Katia Vanden Bulcke; Hubert Vermeersch; Rudi Andre Dierckx; Elena Bonanno; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

3.  Histologic and immunohistochemical characterization of tumor and inflammatory infiltrates in oral squamous cell carcinomas treated with local multikine immunotherapy: the macrophage at the front line.

Authors:  Meora Feinmesser; Elimelech Okon; Ariel Schwartz; Ella Kaganovsky; Britta Hardy; Elena Aminov; Ben Nageris; Jaqueline Sulkes; Raphael Feinmesser
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-10-24       Impact factor: 2.503

Review 4.  Interferons and other cytokines in head and neck cancer.

Authors:  V K Hamasaki; E E Vokes
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

5.  Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck.

Authors:  M E Gore; P Riches; K MacLennan; M O'Brien; J Moore; G Dadian; A Lorentzos; R Garth; E Moskovic; D Archer
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

Review 6.  IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.

Authors:  Gregory T Wolf; Jeffrey S Moyer; Michael J Kaplan; Jason G Newman; James E Egan; Neil L Berinstein; Theresa L Whiteside
Journal:  Onco Targets Ther       Date:  2018-06-28       Impact factor: 4.147

7.  Immunotherapy in head and neck squamous cell carcinoma: a narrative review.

Authors:  Shay Sharon; R Bryan Bell
Journal:  Front Oral Maxillofac Med       Date:  2022-09-10

8.  Systemic therapy strategies for head-neck carcinomas: Current status.

Authors:  Thomas K Hoffmann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20

9.  Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.

Authors:  G Cortesina; A De Stefani; E Galeazzi; G P Cavallo; F Badellino; G Margarino; C Jemma; G Forni
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.